TMEM106B genetics and pathology in Alzheimer’s and related diseases
Official title: Investigating the role of TMEM106b genetics and pathology in Alzheimer’s disease, LATE and FTLD
Funded at University of Miami School of Medicine · NIH-11556657 · Data updated 2026-11-12
Aims to understand how TMEM106B genetic variants and filaments relate to Alzheimer’s disease, FTLD, and LATE so patients and families may benefit from clearer biology and future therapies.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Miami School of Medicine NIH-funded |
| Lab location | 1 site (Coral Gables, United States) |
| Project start | September 22, 2023 |
| Project end | August 31, 2028 |
| Funding year | 2026 |
| Award (this year) | $1,068,401 |
| NIH project number | 7R01NS132330-04 |
| Project ID | NIH-11556657 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients with Alzheimer’s disease, FTLD-TDP, LATE, or related neurodegenerative conditions who donate brain tissue or participate in studies involving TMEM106B analysis.
✕Less likely to help
Individuals without the specified neurodegenerative conditions or without available tissue samples may not directly benefit.
What this research studies
This project investigates how TMEM106B protein filaments and genetic variants may influence disease risk and progression in Alzheimer’s-related conditions. Researchers will study TMEM106B deposition patterns in affected brain tissues and examine how specific genetic changes, like the rs3173615 variant, relate to pathology. The work includes developing an antibody against the TMEM106B filament core to detect these deposits in samples from patients with FTLD-TDP, LATE, and Alzheimer’s disease. Findings could illuminate new targets for diagnostics or treatments in neurodegenerative diseases that affect memory and thinking. The study is conducted at the University of Miami School of Medicine under NIH funding from 2023 to 2028.
Why it matters
Potential benefit: Improved understanding of disease mechanisms that could lead to better diagnostics and future therapies for Alzheimer’s-related conditions.
How similar studies have gone: Previous work has linked TMEM106B variants to disease risk and showed TMEM106B deposition in certain disorders, supporting potential relevance but requiring further validation in Alzheimer’s-related diseases.
Where this research is happening
-
University of Miami School of Medicine
Coral Gables, United States Active
Researchers
- Principal investigator: Petrucelli, Leonard — University of Miami School of Medicine
- Study coordinator: Petrucelli, Leonard
Related research
Other NIH-funded projects on the same topics.
-
Understanding how brain activity changes may drive Alzheimer’s disease progression in a mouse model
Researchers are testing how changes in brain signals and protein cleanup processes affect the development of Alzheimer’s disease in mice.
-
Thiamine-boosting therapy for Alzheimer’s: understanding how benfotiamine may reduce harmful AGE in DP patients
A medication-based approach using high-dose vitamin B1 (benfotiamine) is studied to help people with Alzheimer's by reducing harmful sugar-related molecules.
-
Non-invasive tears biomarker for early Alzheimer's in LMICs
A low-cost, tear-based biomarker approach aims to detect early Alzheimer’s disease in older adults in Peru and similar settings.
-
Turning APOE4 into protective APOE2 or APOE3Christchurch to help with Alzheimer’s
A patient-facing explanation of a treatment idea that aims to change a genetic risk factor for Alzheimer's disease in the brain.
-
Telomerase in Alzheimer’s Disease: how aging biology could influence memory and brain health
Researchers are exploring a new brain-aging mechanism linked to telomerase, with potential to slow or modify Alzheimer’s disease in people and improve cognitive function.
-
Biomarkers of Alzheimer’s Disease: Sensory, Motor, and Cognitive Clues
Researchers are testing simple sensory and movement tasks to find early signs of Alzheimer’s disease so they can diagnose and treat people sooner.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.